Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2024 ▲▼ | Q4 2024 ▲▼ | Change ▲▼ | Q3 2024 ▲▼ | Q4 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Newamsterdam Pharma Company ORDINARY SHARES | 11,831,461 | 10,597,181 | -1,234,280 | $196.40M | $272.35M | 45.97% | +$75.95M |
| Dyne Therapeutics, Inc.(DYN) | 5,954,069 | 5,462,846 | -491,223 | $213.87M | $128.70M | 21.73% | -$85.17M |
| Engene Holdings Inc COM | 8,677,951 | 9,632,561 | +954,610 | $57.27M | $64.06M | 10.81% | +$6.78M |
| Bicycle Therapeutics PlcADS | 2,339,961 | 3,452,330 | +1,112,369 | $52.95M | $48.33M | 8.16% | -$4.62M |
| Replimune Group, Inc.(REPL) | 4,866,449 | 3,970,668 | -895,781 | $53.34M | $48.08M | 8.12% | -$5.25M |
| Astria Therapeutics Inc | 0 | 2,872,537 | +2,872,537 | $0 | $25.68M | 4.34% | +$25.68M |
| Achilles Therapeutics PlcADS | 2,390,050 | 2,390,050 | 0 | $2.44M | $2.75M | 0.46% | +$310.7K |
| Engene Holdings IncW EXP 10 31 2028 *W EXP 10/31/202 | 2,878,148 | 2,878,148 | 0 | $6.04M | $2.43M | 0.41% | -$3.62M |